SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Reven Pharmaceuticals, Inc. – ‘D’ on 3/8/13

On:  Friday, 3/8/13, at 2:19pm ET   ·   Effective:  3/8/13   ·   Accession #:  897069-13-189   ·   File #:  21-192981

Previous ‘D’:  ‘D’ on 1/28/13   ·   Next:  ‘D/A’ on 6/5/13   ·   Latest:  ‘D/A’ on 2/18/15

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 3/08/13  Reven Pharmaceuticals, Inc.       D           3/08/13    1:8K                                     Foley & Lardner/FA

Notice of an Offering of Securities Made Without Registration   —   Form D
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: D           Notice of an Offering of Securities Made Without    HTML      9K 
                          Registration -- primary_doc.xml/7.6                    




        

This ‘D’ Document is an XML Data File that may be rendered in various formats:

  Form D    –   Plain Text   –  SEC Website  –  EDGAR System  –    XML Data    –  <?xml?> File
 

 
SEC Info rendering:  Notice of an Exempt Offering of Securities
 

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL
OMB Number:3235-0076
Estimated average burden
hours per response:4.00

1. Issuer's Identity

CIK (Filer ID Number)Previous Names
  None
Entity Type
1556231
Advanced Diagnostics International of Florida, Inc.
Noventis, Inc.
XCorporation
  Limited Partnership
  Limited Liability Company
  General Partnership
  Business Trust
  Other (Specify)

Name of Issuer
Reven Pharmaceuticals, Inc.
Jurisdiction of Incorporation/Organization
FLORIDA
Year of Incorporation/Organization
XOver Five Years Ago
  Within Last Five Years (Specify Year)
  Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer
Reven Pharmaceuticals, Inc.
Street Address 1Street Address 2
4411 BEE RIDGE ROADSUITE 285
CityState/Province/CountryZIP/PostalCodePhone Number of Issuer
SARASOTAFLORIDA34233941-320-9271

3. Related Persons

Last NameFirst NameMiddle Name
LangePeterB.
Street Address 1Street Address 2
4411 Bee Ridge RoadSuite 285
CityState/Province/CountryZIP/PostalCode
SarasotaFLORIDA34233
Relationship:XExecutive OfficerXDirector  Promoter

Clarification of Response (if Necessary):


Last NameFirst NameMiddle Name
DenommeBrian
Street Address 1Street Address 2
4411 Bee Ridge RoadSuite 285
CityState/Province/CountryZIP/PostalCode
SarasotaFLORIDA34233
Relationship:XExecutive OfficerXDirector  Promoter

Clarification of Response (if Necessary):


Last NameFirst NameMiddle Name
HandleyMichael
Street Address 1Street Address 2
4411 Bee Ridge RoadSuite 285
CityState/Province/CountryZIP/PostalCode
SarasotaFLORIDA34233
Relationship:XExecutive Officer  Director  Promoter

Clarification of Response (if Necessary):


4. Industry Group

  Agriculture
Banking & Financial Services
  Commercial Banking
  Insurance
  Investing
  Investment Banking
  Pooled Investment Fund
Is the issuer registered as
an investment company under
the Investment Company
Act of 1940?
  Yes  No
  Other Banking & Financial Services
  Business Services
Energy
  Coal Mining
  Electric Utilities
  Energy Conservation
  Environmental Services
  Oil & Gas
  Other Energy
Health Care
  Biotechnology
  Health Insurance
  Hospitals & Physicians
XPharmaceuticals
  Other Health Care
  Manufacturing
Real Estate
  Commercial
  Construction
  REITS & Finance
  Residential
  Other Real Estate
  
Retailing
  
Restaurants
Technology
  Computers
  Telecommunications
  Other Technology
Travel
  Airlines & Airports
  Lodging & Conventions
  Tourism & Travel Services
  Other Travel
  
Other

5. Issuer Size

Revenue RangeORAggregate Net Asset Value Range
  No Revenues  No Aggregate Net Asset Value
  $1 - $1,000,000  $1 - $5,000,000
  $1,000,001 - $5,000,000  $5,000,001 - $25,000,000
  $5,000,001 - $25,000,000  $25,000,001 - $50,000,000
  $25,000,001 - $100,000,000  $50,000,001 - $100,000,000
  Over $100,000,000  Over $100,000,000
XDecline to Disclose  Decline to Disclose
  Not Applicable  Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

  Rule 504(b)(1) (not (i), (ii) or (iii))  Rule 505
  Rule 504 (b)(1)(i)XRule 506
  Rule 504 (b)(1)(ii)  Securities Act Section 4(5)
  Rule 504 (b)(1)(iii)  Investment Company Act Section 3(c)
  Section 3(c)(1)  Section 3(c)(9)  
  Section 3(c)(2)  Section 3(c)(10)
  Section 3(c)(3)  Section 3(c)(11)
  Section 3(c)(4)  Section 3(c)(12)
  Section 3(c)(5)  Section 3(c)(13)
  Section 3(c)(6)  Section 3(c)(14)
  Section 3(c)(7)

7. Type of Filing

XNew Notice Date of First Sale 2/5/13   First Sale Yet to Occur
  Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year?
  YesXNo

9. Type(s) of Securities Offered (select all that apply)

  Equity  Pooled Investment Fund Interests
XDebt  Tenant-in-Common Securities
  Option, Warrant or Other Right to Acquire Another Security  Mineral Property Securities
XSecurity to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security  Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
  YesXNo

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor$5,000USD

12. Sales Compensation

Recipient
Recipient CRD Number  None
Futures Investment Company42402
(Associated) Broker or DealerXNone
(Associated) Broker or Dealer CRD NumberXNone
NoneNone
Street Address 1Street Address 2
5914 North 300 West
CityState/Province/CountryZIP/Postal Code
FremontINDIANA46737
State(s) of Solicitation (select all that apply)
Check “All States” or check individual States
  All States
XForeign/non-US
SOUTH DAKOTA
SOUTH CAROLINA
UTAH
ILLINOIS
NEW YORK
INDIANA
GEORGIA
WISCONSIN
ARIZONA
KENTUCKY
CALIFORNIA
MONTANA
LOUISIANA
VIRGINIA
MICHIGAN
OHIO
WYOMING
TEXAS
COLORADO
FLORIDA
IOWA
NORTH CAROLINA
NEBRASKA

13. Offering and Sales Amounts

Total Offering Amount$1,000,000USD
or  Indefinite
Total Amount Sold$22,500USD
Total Remaining to be Sold$977,500USD
or  Indefinite

Clarification of Response (if Necessary):

May increase the offering to $2,000,000 of Notes.

14. Investors

  
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
2

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions$0USD
  Estimate
Finders' Fees$0USD
  Estimate

Clarification of Response (if Necessary):

The Selling Agent will be compensated solely in Shares equal to 4% of the first $500,000, 3% of the next $1,000,000, and 2% of the final $1,000,000 sold in the Offering at ten cents ($0.10) per Share.

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

$54,000USD
XEstimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:
  • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
  • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
  • Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

IssuerSignatureName of SignerTitleDate
Reven Pharmaceuticals, Inc.Peter B. LangePeter B. LangePresident 3/8/13

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


Top
Filing Submission 0000897069-13-000189   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., Mar. 19, 12:40:00.2am ET